The application for the marketing authorization was Emerflu the Agency on 27 April 2007 presented. Emerflu received a negative opinion of the Committee for Human Medicinal Products on 19 March 2009 and the time of cancellation, a decision of the European Commission was pending.
Notes1 This press release, together with all relevant documents on on the Agency website. The question – and – answer document on the negative comments on the Agency’s website. Withdrawal an application does not affect the ability of the Company submit a new application at a later time.,, South and Nigeria, ‘in particular’must their commitment to the initiative show be met for the comprehensive management target in the next eight months of, say by the WHO HIV / AIDS Programme Director Jim Yong Kim, the editors. If the 3 by 5 Initiative of did that ‘political force ‘influence South Africa into to implementation of its recommendations , the three million treatment courses target be be ‘more likely ‘reached after the Lancet. Says, ‘Without South Africa on board, and its 837,000 people affected by HIV / AIDS and its lead in Africa, 3 5 just a fantasy,’the editor.. Countries which Barriers ‘ into Reaching WHO 3 by 5 the initiative Treatment target exists said There are There is ‘enormous barriers ‘attain the objective of achieve the goal of to the World Health Organisation 3 by 5 initiative to three million people by ARVs by 2005.